戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 gulation and other analytical limitations of coagulation tests.
2  Ab1 showed anticoagulant activity by global coagulation tests.
3 tivity, but demonstrate inhibition of global coagulation tests.
4 f normal cFIX antigen levels, which improved coagulation tests.
5 bin 16 g/dl), with normal liver function and coagulation testing.
6 etry panels, parathyroid hormone assays, and coagulation testing.
7  The method could extend and improve current coagulation testing.
8                                              Coagulation testing aids anesthesiologists in diagnosis
9 anding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation o
10 nificant coagulopathy (as defined by routine coagulation tests) and is used to justify preprocedure u
11 itory effect on PL-restricted in vitro blood coagulation tests, and are comprised mainly of Ab agains
12 val, expression levels, in vitro and in vivo coagulation tests, and histopathology for up to 16 month
13 s been reinforced by the fact that screening coagulation tests (APTT, prothrombin time--INR) are ofte
14                                       Global coagulation tests are most useful in detecting overt con
15               In addition, in most patients, coagulation tests are not sensitive to increases in coag
16 ally ill patients with deranged conventional coagulation tests are often perceived to have an increas
17                                      Routine coagulation tests are poor determinants of bleeding risk
18 says for platelet, neutrophil functions, and coagulation tests, as well.
19  with TBI have abnormalities on conventional coagulation tests at admission to the emergency departme
20 lation has been difficult using conventional coagulation tests, but thrombocytopenia, fibrin polymeri
21 , although some of the more widely available coagulation tests can provide information that is potent
22              To measure PT/INR, conventional coagulation testing (CCT) is performed, which is time-co
23             Admission data from conventional coagulation tests (CCT), rotational thrombelastometry (R
24 ormal coagulation parameters in conventional coagulation tests (CCTs).
25 nd shock lead to alterations in conventional coagulation tests (CCTs).
26                                              Coagulation tests following the administration of factor
27 mbolism or the introduction of a more global coagulation test for screening.
28                                  Traditional coagulation tests for assessing vitamin K status are non
29                                 Viscoelastic coagulation tests have been established as a rapid and r
30                                 Viscoelastic coagulation tests have been increasingly used for hemost
31 chest tube bleeding, whereas platelet count, coagulation tests, heparin dose, and thrombotic events w
32  thromboelastometry (ROTEM) and conventional coagulation testing in patients with Crimean-Congo haemo
33 coagulation assessment was based on standard coagulation tests in 8 centers (50%), on viscoelastic as
34 nicopathological characteristics and routine coagulation tests including prothrombin time, and intern
35 n thrombin substrates and has no activity in coagulation tests or platelet aggregation.
36 ma transfusion in either correcting abnormal coagulation tests or reducing perceived risk of hemorrha
37 1% (10 of 123) of patients with any abnormal coagulation test results and 9.7% (85 of 877) of patient
38       Plasma transfusion to correct abnormal coagulation test results prior to an invasive procedure
39 clinicians in the setting of mildly abnormal coagulation test results, and there is no evidence that
40                                              Coagulation test screening, including the measurement of
41                                 Viscoelastic coagulation tests (such as ROTEM or TEG) have emerged as
42 ancer range from asymptomatic basic abnormal coagulation tests to massive clinical thromboembolism, w
43                          Existing laboratory coagulation testing was originally designed for evaluati
44 ted and blood samples for ROTEM analysis and coagulation testing were drawn at admission and during h
45                                              Coagulation tests were normalized, no bleeding had occur
46                          Abnormal results of coagulation tests were not correlated with an increased
47                                              Coagulation tests (whole blood clotting time [WBCT], act
48 tometry/platelet aggregometry), conventional coagulation tests, whole blood counts, and platelet flow
49 dministered to address abnormal preoperative coagulation tests, with the hope to mitigate bleeding co